Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

1. Servitja, S.
2. Ramos, M.
3. Gil, M.
4. Sánchez-Rovira, P.
5. Vázquez-Estevez, S.
6. Virizuela, J.A.
7. García-Estevez, L.
8. Velasco, A.
9. Tusquets, I.